P625: Utility of highest pathogenic variant frequency approach for application of BA1/BS1 ACMG criteria to reduce variants of uncertain significance

• Kyle Salsbery,
• Devin Oglesbee,
• Elizabeth Selner,
• Angela Pickart,
• Zhiyv Niu,
• Emily Lauer,
• Dawn Peck

Affiliations

Kyle Salsbery

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Devin Oglesbee

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Elizabeth Selner

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Angela Pickart

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Zhiyv Niu

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Emily Lauer

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Dawn Peck

Laboratory Genetics and Genomics, Department Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN